Novo Nordisk Cuts Forecast Amid Growing Competition
Novo Nordisk (NVO) lowers 2025 guidance for the fourth time as Wegovy and Ozempic sales slow. New CEO battles Eli Lilly competition while pursuing $10B Metsera acquisition.
/ 919 items
#Healthcare↓
Teva Pharmaceuticals Beats Q3 Expectations as Branded Drug Strategy Pays Off
Teva Pharmaceuticals (TEVA) Q3 2025 earnings beat expectations with 33% growth in branded drugs led by Austedo. Stock surges 12% as innovative portfolio drives transformation.
Humana Beats Q3 Profit Expectations Despite Rising Medical Costs
Humana's Q3 earnings surpass Wall Street forecasts with $3.24 adjusted EPS. Medicare Advantage membership outlook improves while company manages rising healthcare costs.
FDA Rejects Biohaven's Troriluzole for Rare Neurological Disease, Company Slashes R&D Budget
FDA denies Biohaven's troriluzole approval for spinocerebellar ataxia citing real-world evidence concerns. Company cuts R&D spending 60% and refocuses on three key late-stage programs.
Tempus AI Hits Major Profit Goal Amidst Rapid Q3 2025 Growth
Tempus AI achieved its 10-year profitability target in Q3 2025, driven by massive 84.7% revenue growth and exceptional performance in its genomics and clinical testing divisions.
QIAGEN Acquires Parse Biosciences to Boost Single-Cell Research Capabilities
QIAGEN announces its $225 million acquisition of Parse Biosciences, expanding into scalable single-cell technologies to power AI-driven biological research and drug discovery.